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Questionable questionnaire
To the Editor: Question 8 of November 2009’s SAMJ CPD reads 
as follows: ‘Many new cases of tuberculosis are infected with 
multiple drug-resistant organisms.’ True or false?
While I admit that any new TB case in South Africa is 
regrettable, and that we have to adapt our treatment regimen 
to accommodate the sad fact of MDR-TB, I would not call 1.8% 
of new TB cases ‘many’; in effect, that is quite a small number, 
statistically speaking. Would you describe a salary increase of 
1.8% as large? Or call it a very small increase?
According to the Global Alliance for TB Drug Development 
(http://www.tballiance.org/why/mdr-tb.ph), ‘The WHO 
estimates that MDR-TB makes up greater than 10 percent of all 
new TB cases in Eastern Europe, the region most affected by 
the disease. Rates of up to six percent have been reported in 
many countries.’
Aha! Six to 10% seems to be ‘many’, so 1.8% is still a few 
– relatively speaking.
In addition, at http://www.globalhealthreporting.org/
article.asp?DR_ID=56031: ‘According to the study, about 25% 
of all new TB cases in China and about 50% of all previously 
treated cases are resistant to at least one TB drug.’
Now 25% – that really is many – puts South Africa’s 1.8% to 
shame, doesn’t it?
To conclude: ‘Few’ and ‘many’ are relative and subjective 
terms, and I believe that subjectively termed questions should 
not appear in CPD questionnaires, as the former do not 
necessarily have hard and fast answers which can’t be debated.
Petrus van Staden
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We stand corrected! – Editor
A case of a combined commonly  
inherited bleeding and clotting disorder
To the Editor: We report the uncomplicated outcome of 
pregnancy in a patient with a combined bleeding and 
clotting disorder managed with ante- and postpartum 
thromboprophylaxis.
A 30-year-old woman was referred for screening for an 
inherited thrombophilia. Her brother had developed a life-
threatening deep-vein thrombosis after a mild sports injury. 
A noteworthy finding on personal history was easy bruising. 
Thrombotic screen testing revealed a heterozygous factor V 
Leiden mutation and a bleeding screen type I von Willebrand 
disease (vWD). She later presented at 12 weeks’ gestation with 
her first pregnancy. Factor VIII, von Willebrand factor (VWF) 
antigen and activity levels measured at presentation and in the 
third trimester were in the normal range. Thromboprophylaxis 
with enoxaparin 20 mg daily (weight 56 kg) was prescribed 
from 32 weeks’ gestation until 4 weeks before delivery. Anti-
Xa activity and platelet counts were monitored. She went into 
preterm labour and delivered a male baby by caesarean section. 
The factor V Leiden mutation is the most frequent cause 
of familial thrombosis and vWD is the most common 
inherited bleeding disorder.1,2 Concurrence of these disorders 
is estimated to occur in 0.25% of Caucasians and poses 
therapeutic challenges, particularly in pregnancy. 
Pregnancy is physiologically associated with a 
hypercoagulable state and an increased risk of venous 
thrombo-embolism (VTE), with a risk of 1/1 000 deliveries.3 
In pregnancy FVIII and VWF levels normalise, thereby 
ameliorating the bleeding risk. The presence of the factor V 
Leiden mutation increases the risk of VTE and pregnancy-
related morbidity to 1/500.4 Pregnancy-related complications 
include recurrent miscarriages, pre-eclampsia, placental 
abruption and intra-uterine growth restriction.5 However, 
the use of thromboprophylaxis in the management of 
pregnant women with a known thrombophilia and no prior 
VTE is based on case-control studies and a small number of 
prospective studies. 
Management of these patients therefore remains 
controversial. The American College of Chest Physicians 
2008 guidelines recommends postpartum prophylaxis for 4 
- 6 weeks (grade 2C). After delivery the patient’s risk should 
be individually assessed to determine whether prophylaxis 
is indicated (grade 1C).3 In view of this patient’s significant 
family history she was managed with both ante- and 
postpartum prophylaxis. 
Heparins are the preferred drug during pregnancy because 
they do not cross the placenta,3 and low-molecular-weight 
heparin (LMWH) is preferred to unfractionated heparin.6 
Monitoring of LMWH anti-Xa levels is recommended 3 hours 
after injection, with adjustment of the dose to maintain a level 
of 0.2 - 0.6 IU.3
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